Table 2.
Adverse events with onset after TIL infusion among all treated patients (N=21)
| Adverse Event Term, n (%) | All Treated Patients |
|---|---|
| (N=21) | |
| Thrombocytopenia | 13 (62) |
| Pyrexia | 12 (57) |
| Rigors | 9 (43) |
| Neutropenia | 6 (29) |
| Tachycardia | 6 (29) |
| Pulmonary edema | 5 (24) |
| Vascular leak | 5 (24) |
| Rash | 4 (19) |
| Atrial fibrillation | 3 (14) |
| Cardiovascular instability | 3 (14) |
| Chest infection | 3 (14) |
| Edema | 3 (14) |
| Confusion | 2 (10) |
| Hypokalemia | 2 (10) |
| Hypotension | 2 (10) |
| Neurological deficit | 2 (10) |
| Renal impairment | 2 (10) |
| Respiratory sepsis | 2 (10) |
| Seizure | 2 (10) |
| Sepsis | 2 (10) |
| Vitiligo | 2 (10) |
| Weight gain | 2 (10) |
| Wheezing | 2 (10) |
| Cough | 1 (5) |
| Diarrhea | 1 (5) |
| Dysphasia | 1 (5) |
| Engraftment syndrome | 1 (5) |
| Hallucinations | 1 (5) |
| Lethargy | 1 (5) |
| PICC line infection | 1 (5) |
| Pleural effusion | 1 (5) |
| Pneumonia | 1 (5) |
| Pneumonitis | 1 (5) |
| Respiratory problems | 1 (5) |
| Tachypnea | 1 (5) |
PICC, peripherally inserted central catheter; TIL, tumor-infiltrating lymphocyte.